Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Abstract Text:

    kristian reichKristian Reich,frank o nestleFrank O Nestle,ying wuYing Wu,mohan balaMohan Bala,debra eisenbergDebra Eisenberg,cynthia guzzoCynthia Guzzo,shu liShu Li,lisa t dooleyLisa T Dooley,christopher e m griffithsChristopher E M Griffiths,kristian reichKristian Reich,frank o nestleFrank O Nestle,ying wuYing Wu,mohan balaMohan Bala,debra eisenbergDebra Eisenberg,cynthia guzzoCynthia Guzzo,shu liShu Li,lisa t dooleyLisa T Dooley,christopher e m griffithsChristopher E M Griffiths,

    This study examined the impact of infliximab maintenance therapy on productivity in patients with moderate-to-severe psoriasis. Patients from the multicentre, double-blind, placebo-controlled EXPRESS study (n = 378) were randomised to receive infusions of placebo or infliximab 5 mg/kg at weeks 0, 2, and 6 and every 8 weeks through week 46, with placebo crossover to infliximab at week 24. Main outcome measures were a 10-cm productivity visual analog scale (VAS), role-physical and role-emotional domain scores of the Short Form 36-Item questionnaire (SF-36), and Dermatology Life Quality Index (DLQI) scores. The productivity VAS score was 5.9 cm at baseline. Mean change through week 10 with infliximab was significantly greater than that with placebo (2.7 cm vs. - 0.1 cm) and was sustained through week 24. Similar trends were observed for SF-36 scores. The proportion of patients whose skin condition prevented them from working and/or studying per DLQI scores decreased through week 10 with infliximab (12.1% and 1.4%, respectively), but increased slightly with placebo (9.1% and 11.6%, respectively). At week 50, improvements in productivity and SF-36 scores were sustained with infliximab. In placebo patients who crossed over to infliximab, these scores improved and approached those seen with infliximab at week 50. Infliximab significantly improved productivity and ability to work in psoriasis patients.

    Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Publishing Authors By Initials

    k reichK Reich,fo nestleFO Nestle,y wuY Wu,m balaM Bala,d eisenbergD Eisenberg,c guzzoC Guzzo,s liS Li,lt dooleyLT Dooley,ce griffithsCE Griffiths,k reichK Reich,fo nestleFO Nestle,y wuY Wu,m balaM Bala,d eisenbergD Eisenberg,c guzzoC Guzzo,s liS Li,lt dooleyLT Dooley,ce griffithsCE Griffiths,

    For similar abstracts research abstracts see: abstracts research

    PUBMED ID PMID:

    MEDLINE DATE:

    Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Journal Published:

    PUBLICATION TYPE: Research Support, Non-U.S. Gov

    Journal: European journal of dermatology : EJD

    VOLUME: 17

    Page Numbers: 381-6

    Journal Abbreviation:

    ISSN: 1167-1122

    DAY: 2

    MONTH: 08

    YEAR: 2007

    Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Information

    Number of References:

    LANGUAGE: eng

    NlmUniqueID: 9206420

    Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Keywords Mesh Terms:

    KEYWORDS:

    MESH TERMS:

    Chemical & Substance for Abstract: Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis. Information

    Substance Name:

    Registry Number:

    Grant and Affiliation Information for Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis.

    AFFILIATION: Department of Dermatology, Georg-August University; Von-SieboldStrasse 3, 37075, Göttingen, Germany.

    Country: France

    France Research PublicationFrance Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Eur J Dermatol

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Infliximab treatment improves productivity among patients with moderate-to-severe psoriasis Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News